HHS says Ste­lara may be de­s­e­lect­ed from Medicare ne­go­ti­a­tions, de­pend­ing on biosim­i­lar launch

John­son & John­son’s Ste­lara may not be on CMS’ Medicare ne­go­ti­a­tions list for long, HHS ac­knowl­edged in court doc­u­ments filed last week.

The first 10 drugs se­lect­ed by CMS un­der the In­fla­tion Re­duc­tion Act will be sub­ject to ne­go­ti­at­ed prices start­ing in 2026, as long as they have no “mean­ing­ful com­pe­ti­tion,” ac­cord­ing to the cur­rent guide­lines. While it’s un­clear ex­act­ly where that bar stands, HHS thinks it’s a dis­tinct pos­si­bil­i­ty for Ste­lara, which is ex­pect­ed to have a biosim­i­lar ri­val by 2025.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER